Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

China Biologic’s Revenues and Profits Soar in Q3

publication date: Nov 13, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

China Biologic Products, enjoying higher prices for its products and lower operating expenses, reported a very substantial 54% rise in Q3 revenues to $13.8 million. Net income climbed an even larger 98% to $4.5 million, which works out to 21 cents per share, fully diluted. Prices for China Biologic’s plasma-centered portfolio increased 22% during the period, a major factor in the company’s success. More details...

Stock Symbol: (OTCBB: CBPO)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...